CE Mark for IM RefluxStop device to treat Gastro-osophageal Reflux Disease (GERD).- Implantica.
CE Mark approval has been granted on 8 August 2018 for the IM RefluxStop device, from Implantica, to treat patients suffering from Gastro-osophageal Reflux Disease (GERD/GORD). The approval enables Implantica to market and sell RefluxStop in member countries of the European Economic Area and Switzerland.
Comment: IM RefluxStop treats acid reflux without affecting the food passageway, a novel method that will possibly create a paradigm shift in acid reflux treatment. This device is a non-active implant and is placed on the upper part of the stomach through laparoscopic (key hole) surgery.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.